Literature DB >> 2309904

Effect of human recombinant superoxide dismutase on canine myocardial infarction.

B S Patel1, M O Jeroudi, P G O'Neill, R Roberts, R Bolli.   

Abstract

To determine whether human recombinant superoxide dismutase (h-SOD) produces sustained reduction of infarct size, anesthetized dogs underwent a 2-h coronary occlusion followed by either 48 or 4 h of reperfusion. In the 48-h study, dogs were randomized to three intravenous treatments: 1) "low-dose" h-SOD (2 mg/kg bolus 2 min before reperfusion followed by 4 mg/kg over 45 min), 2) "high-dose" h-SOD (8 mg/kg bolus 2 min before reperfusion followed by 8 mg/kg over 45 min), or 3) equivalent volumes of saline. In the 4-h study, dogs were randomized to high-dose h-SOD or saline. Occluded bed size was measured by postmortem perfusion and infarct size by triphenyl tetrazolium chloride staining and planimetry. Investigators performing the study and measuring infarct size were blinded to the treatment given. High plasma concentrations of h-SOD were present in the arterial blood of treated dogs in the early phase of reperfusion (greater than 60 and greater than 180 micrograms/ml in low- and high-dose groups, respectively). In both studies, control and treated groups were similar with respect to occluded bed size, collateral blood flow, and rate-pressure product during ischemia. In the 48-h study, infarct size, expressed as percent of occluded bed size, was 41.3 +/- 7.6% (mean +/- SE) in the control group, 37.1 +/- 7.2% in the low-dose h-SOD group, and 48.0 +/- 7.1% in the high-dose h-SOD group. In the 4-h study, infarct size was 30.6 +/- 4.9% in the control group and 31.5 +/- 9.6% in the high-dose h-SOD group. Analysis of the flow-infarct relationships confirmed that h-SOD did not reduce infarct size at any level of collateral flow in either the 48- or 4-h study. Recovery of regional myocardial function after reperfusion was also unaffected by h-SOD in both studies. Thus in this randomized blinded study, large doses of h-SOD given at the time of reperfusion failed to limit infarct size or enhance recovery of function, both early (4 h) and late (48 h) after reperfusion following a 2-h coronary occlusion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309904     DOI: 10.1152/ajpheart.1990.258.2.H369

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Comparison of the effects of different magnesium administration times on infarct size.

Authors:  Diego R Martínez Demaría; Horacio E Cingolani; Susana M Mosca
Journal:  Exp Clin Cardiol       Date:  2003

2.  Delineating the relationships among the formation of reactive oxygen species, cell membrane instability and innate autoimmunity in intestinal reperfusion injury.

Authors:  Haekyung Lee; Eun Hee Ko; Mark Lai; Na Wei; Javi Balroop; Zerin Kashem; Ming Zhang
Journal:  Mol Immunol       Date:  2013-12-22       Impact factor: 4.407

Review 3.  Oxygen-derived free radicals and myocardial reperfusion injury: an overview.

Authors:  R Bolli
Journal:  Cardiovasc Drugs Ther       Date:  1991-03       Impact factor: 3.727

4.  Loss of plasma membrane integrity, complement response and formation of reactive oxygen species during early myocardial ischemia/reperfusion.

Authors:  Pradeepkumar Charlagorla; Junying Liu; Monaliben Patel; Julie I Rushbrook; Ming Zhang
Journal:  Mol Immunol       Date:  2013-08-01       Impact factor: 4.407

5.  Demonstration of an early and a late phase of ischemic preconditioning in mice.

Authors:  Y Guo; W J Wu; Y Qiu; X L Tang; Z Yang; R Bolli
Journal:  Am J Physiol       Date:  1998-10

6.  Significant reduction of ischemia-reperfusion cell death in mouse myocardial infarcts using the immediate-acting PrC-210 ROS-scavenger.

Authors:  Timothy A Hacker; Gaoussou Diarra; Bryan L Fahl; Susan Back; Erin Kaufmann; William E Fahl
Journal:  Pharmacol Res Perspect       Date:  2019-07-12

Review 7.  Drug antioxidant effects. A basis for drug selection?

Authors:  B Halliwell
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.